Table 15.10

Immunosuppression Use for Maintenance by Regimen

Two Years Following Transplantation, 1998 to 2004

Recipients with Kidney-Pancreas Transplants

  Transplant Year
1998 1999 2000 2001 2002 2003 2004
Transplants 972 941 915 891 905 871 881
Functioning Graft at 2 Years PostTx 829 817 796 750 777 747 750
With Maintenance Use Recorded at 2 Years PostTx 797 786 780 723 766 737 733
--- + MMF/MPA 0.0% 0.0% 0.0% 0.1% 0.0% 0.3% 0.4%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.6% 0.3% 1.8% 4.6%
--- + MMF/MPA + Steroids 0.4% 0.5% 0.3% 0.8% 0.9% 0.0% 1.2%
--- + OtherAntimet + Steroids 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.4% 0.1% 0.1%
--- + Siro/Evero + Steroids 0.0% 0.6% 0.5% 0.3% 0.4% 0.7% 0.1%
--- + Steroids 0.4% 0.3% 0.0% 0.8% 0.8% 0.5% 0.1%
CyA 0.1% 0.0% 0.0% 0.1% 0.4% 0.0% 0.0%
CyA + MMF/MPA 0.0% 0.0% 0.0% 0.3% 0.3% 0.4% 0.4%
CyA + MMF/MPA + Siro/Evero 0.0% 0.1% 0.3% 0.0% 0.0% 0.0% 0.1%
CyA + MMF/MPA + Steroids 23.6% 19.5% 11.0% 9.3% 8.4% 7.3% 3.4%
CyA + OtherAntimet 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Steroids 1.4% 0.1% 0.1% 0.1% 0.4% 0.0% 0.3%
CyA + Siro/Evero 0.0% 0.1% 0.1% 0.3% 0.3% 1.2% 1.8%
CyA + Siro/Evero + Steroids 0.4% 0.9% 2.6% 2.6% 1.0% 1.5% 0.3%
CyA + Steroids 1.3% 1.0% 1.3% 1.1% 0.1% 0.4% 0.4%
Tac 0.6% 0.1% 0.3% 1.8% 2.5% 1.4% 1.5%
Tac + MMF/MPA 1.4% 2.4% 3.7% 5.3% 6.0% 7.3% 13.8%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.3% 1.0% 0.4% 1.1% 1.0%
Tac + MMF/MPA + Steroids 53.1% 55.9% 53.2% 46.7% 49.0% 51.3% 51.8%
Tac + OtherAntimet 0.3% 0.5% 0.1% 0.0% 0.3% 0.1% 0.4%
Tac + OtherAntimet + Steroids 4.0% 3.3% 2.8% 0.8% 2.5% 1.8% 1.5%
Tac + Siro/Evero 0.0% 0.4% 3.3% 7.7% 8.2% 9.4% 5.9%
Tac + Siro/Evero + Steroids 1.4% 2.0% 6.4% 11.1% 8.6% 5.0% 5.5%
Tac + Steroids 7.4% 7.5% 5.9% 5.1% 5.0% 4.9% 2.7%
Other Regimen 4.3% 4.7% 7.6% 3.9% 4.0% 3.5% 2.6%


Source: OPTN/SRTR Data as of May 1, 2007.

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.

Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.